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ORAL PRESENTATION Open Access
Chemotherapeutics for vivax malaria
J Kevin Baird
From Challenges in malaria research
Basel, Switzerland. 10-12 October 2012
Plasmodium vivax imposes significant burdens of mor-
bidity and mortality across the malaria endemic world.
Treatment of this infection requires a blood schizonto-
cide against the acute attack and hypnozoitocide against
relapses. Chloroquine combined with primaquine has
been the therapy of choice for radical cure of vivax
malaria since the 1950s. Primaquine, however, was
never optimized or adapted for use in endemic zones
and its toxicity in prevalent G6PD-defkient patients
(typically 5-20%) sharply limits its effectiveness. Resis-
tance to chloroquine has emerged in Southeast Asia and
now threatens the Indian sub-continent where most
P. vivax occurs. The research community faces the steep
challenge of developing new radical cure strategies. This
presentation explores those challenges and the means to
meet them, principally optimizing primaquine as a partner
to new ACTs for maximum efficacy and more practical
dosing and safety.
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